Thomas F. Chen is an Independent Director of the Company. Mr. Chen served as Senior Vice President and President of International Nutrition of Abbott Laboratories (Abbott), a global health care company, before retiring in 2010. During his 22-year career at Abbott, Mr. Chen served in a number of roles with expanding responsibilities, primarily in Pacific/Asia/Africa where he oversaw expansion into emerging markets. Prior to Abbott, he held several management positions at American Cyanamid Company, which later merged with Pfizer Inc. Mr. Chen currently serves as a director of Stericycle, Inc. and an advisor to Cooperation Fund, a partnership between Goldman Sachs and the sovereign fund, China Investment Cooperation, to bolster U.S. manufacturers’ market presence in China. Mr. Chen previously served as a director of Cyanotech Corporation.
As the Independent Director of Baxter International, the total compensation of Thomas Chen at Baxter International is $298,589. There are 21 executives at Baxter International getting paid more, with Jose Almeida having the highest compensation of $13,913,800.
Thomas Chen is 70, he's been the Independent Director of Baxter International since 2012. There are 4 older and 24 younger executives at Baxter International. The oldest executive at Baxter International Inc. is James Gavin, 74, who is the Independent Director.
Thomas's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney, eJeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: